Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human Fc gamma RI / CD64 Protein, His,Avitag™ (MALS verified), 25 µg  

Recombinant Biotinylated Human Fc gamma RI / CD64 Protein, His,Avitag™ (MALS verified), 25 µg

Recombinant Biotinylated Human Fc gamma RI / CD64 Protein, AA Gln 16 - Pro 288, expressed from human 293 cells (HEK293), His,Avitag™ (MALS verified)

Synonym: Recombinant, human, protein, FCGR1A, FCG1, FCGR1, IGFR1, CD64, CD64A, FCRI

More details

FCA-H82E8-25

Availability: within 7 days

420,00 €

Background
Receptors that recognize the Fc portion of IgG are divided into three groups designated Fc gamma RI, RII, and RIII, also known respectively as CD64, CD32, and CD16. Fc gamma RI binds IgG with high affinity and functions during early immune responses. Fc gamma RII and RIII are low affinity receptors that recognize IgG as aggregates surrounding multivalent antigens during late immune responses. High affinity immunoglobulin gamma Fc receptor I is also known as FCGR1A, FCG1, FCGR1, CD64 and IGFR1, is a type of integral membrane glycoprotein that binds monomeric IgG-type antibodies with high affinity, which belongs to the immunoglobulin superfamily or FCGR1 family. FCGR1A / CD64 contains 3 Ig-like C2-type (immunoglobulin-like) domains. CD64 is constitutively found on only macrophages and monocytes, but treatment of polymorphonuclear leukocytes with cytokines like IFNγ and G-CSF can induce CD64 expression on these cells.

Source
Recombinant Biotinylated Human CD64, His,Avitag (FCA-H82E8) is expressed from human 293 cells (HEK293). It contains AA Gln 16 - Pro 288 (Accession # P12314-1).
Predicted N-terminus: Gln 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 34.2 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "High expression of neutrophil and monocyte CD64 with simultaneous lack of upregulation of adhesion receptors CD11b, CD162, CD15, CD65 on neutrophils in severe COVID-19"
Karawajczyk, Douhan Håkansson, Lipcsey et al
Ther Adv Infect Dis (2021) 8, 20499361211034065
(2) "Microfluidic Chips for Sepsis Diagnosis"
Zhou, Yang, Pappas
Methods Mol Biol (2021) 2321, 207-219
(3) "Blood neutrophils from children with COVID-19 exhibit both inflammatory and anti-inflammatory markers"
Seery, Raiden, Algieri et al
EBioMedicine (2021) 67, 103357
Showing 1-3 of 756 papers.
Please refer to product data sheet.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrobiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.